(Q36926626)

17 August 2017

1 reference

title

What have we learned from large drug treatment trials in COPD? (English)

1 reference

17 August 2017

Peter M A Calverley

1

1 reference

PubMed ID

17765527

17 August 2017

Stephen I Rennard

series ordinal

2

1 reference

PubMed ID

17765527

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

370

1 reference

17 August 2017

9589

1 reference

17 August 2017

774-785

1 reference

Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Epidemiology and costs of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Mortality in relation to smoking: 40 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A dynamic population model of disease progression in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The natural history of chronic airflow obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Smoking and lung function of Lung Health Study participants after 11 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Prognosis in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Characteristics of physical activities in daily life in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Salmeterol reduces dyspnea and improves lung function in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Bronchodilator response in the lung health study over 11 yrs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Health status measured with the CRQ does not predict mortality in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Health status measurement in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Impact of preventing exacerbations on deterioration of health status in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Physiological changes during symptom recovery from moderate exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Mortality in COPD: Role of comorbidities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

A pilot study of all-trans-retinoic acid for the treatment of human emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Statin use is associated with reduced mortality in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961381-6

7 January 2021

10.1016/S0140-6736(07)61381-6

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17765527